In preclinical models of TNBC, IL-8 inhibition was shown to revert the mesenchymal phenotype, decrease MDSCs in the TME and enhance tumor cell killing by T and NK cells (202), providing the rational for combining IL-8 inhibitors with immunotherapy or chemotherapy. This evidence concerns the gene CXCL8 and neoplasm.